The opinion magazine of the American Gastroenterological Association
As physicians, we have grown accustomed to the concept of screening for and surveillance of those found to have premalignant conditions with the expectation that by doing so we can prevent cancer and do little if any harm. In reality this concept has rarely been demonstrated to be true and indeed we often do great […]
Roughly one-fifth of all human cancers arise in the gastrointestinal tract. Worldwide, over 3.5 million patients are newly diagnosed with GI tract cancer each year, of whom 310,000 are in the U.S. alone. These malignancies show marked gender, racial and socioeconomic differences in incidence. For instance, esophageal and gastric adenocarcinomas occur more frequently in U.S. […]
Chances are good that either you, or someone you work with, are suffering from some degree of burnout. Chances are even better that you don’t know it. Burnout isn’t the same as stress. It’s not about being tired, and it’s not about being depressed. Burnout is a state of emotional and mental exhaustion in your […]
As a disclaimer, I am not an email expert or aficionado. I am someone who constantly battles the daily onslaught of managing three email accounts, which includes my work and professional life. I have learned some tips from trial and error and in talking to others, and I have found that by following these steps, […]
Combination direct-acting antiviral (DAA) therapy of eight to 24 weeks for the treatment of chronic hepatitis C is highly effective. Current guidelines do not encourage treatment for less than 12 weeks. However, mounting evidence indicates that many patients can achieve sustained virologic response (SVR) with only eight weeks of treatment. Thus, treatment for shorter durations […]
Acute alcoholic hepatitis is a clinical syndrome characterized by sudden onset of jaundice, malaise, anorexia and occasionally abdominal pain associated with fever, tachycardia, leukocytosis and other evidence of a systemic inflammatory response in an individual who has been drinking heavily within the preceding eight weeks. By definition, serum bilirubin is elevated with modest elevation in […]
With the recent approvals of infliximab biosimilars, CT-P13 and SB2, and adalimumab biosimilar, ABP 501, by the U.S. FDA, the landscape of available anti-tumor necrosis factor (TNF) therapies for the treatment of inflammatory bowel disease (IBD) is changing right before our eyes. To understand the implications of this change, it is important to consider several […]
One of the most common clinical challenges that endoscopists encounter is how to properly manage antithrombotic agents in patients undergoing endoscopic procedures. Optimal management requires strategies individualized to specific patients. Physicians must consider the bleeding risk of the endoscopic procedure being performed, the underlying patient condition necessitating the antithrombotic therapy and the specific characteristics of […]
As physicians, we have grown accustomed to the concept of screening for and surveillance of those found to have premalignant conditions with the expectation that by doing so we can prevent cancer and do little if any harm. In reality this concept has rarely been demonstrated to be true and indeed we often do great […]
Roughly one-fifth of all human cancers arise in the gastrointestinal tract. Worldwide, over 3.5 million patients are newly diagnosed with GI tract cancer each year, of whom 310,000 are in the U.S. alone. These malignancies show marked gender, racial and socioeconomic differences in incidence. For instance, esophageal and gastric adenocarcinomas occur more frequently in U.S. […]
Stay Connected